Share This Article:

Comparative Kinetics of Immune Responses and Changes in Cellular Sub-Sets Detected in Colorectal Cancer Patients Vaccinated with MVA-5T4 (TroVax) Administered Alongside Two Different Chemotherapy Regimens

Abstract Full-Text HTML Download Download as PDF (Size:519KB) PP. 54-64
DOI: 10.4236/jct.2011.21006    4,016 Downloads   7,878 Views  

ABSTRACT

Modified vaccinia Ankara (MVA) virus encoding the tumor antigen 5T4 (MVA-5T4; TroVax?) has been tested in two open-label phase II studies in metastatic colorectal cancer patients alongside two chemotherapy regimens, 5-fluorouracil, folinic acid and irinotecan (IrMdG) or 5-fluorouracil, folinic acid and oxaliplatin (OxMdG). The aim of this study was to investigate the kinetics of immune responses and changes in cellular sub-sets before, during and after treatment with each chemotherapy regimen. In total, 23 patients received the complete course of treatment which comprised 2 injections before, during and after completion of chemotherapy. Antibody and cellular responses specific for 5T4 and MVA were monitored throughout the study and changes in immune cell subsets were determined. All 23 evaluable patients mounted MVA- and 5T4-specific cellular and/or humoral responses. Patients on both trials showed significant reductions in the numbers of neutrophils and the proportion of regulatory T cells (Treg) within the CD4+ T cell population. Monocyte and NK cell numbers decreased significantly in patients treated with IrMdG but not OxMdG. The largest increase in 5T4-specific cellular responses was observed 2 weeks following the completion of chemotherapy which was coincident with a decrease in Treg levels. Both chemotherapy regimens resulted in a significant decrease in the proportion of peripheral Tregs. Levels of Tregs during chemotherapy showed an inverse correlation with 5T4 cellular responses detected immediately post-chemotherapy. These data may support a rationale for sequencing chemotherapy with immunotherapy strategies at time points when Treg levels are predicted to be low.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

M. Kelleher, W. Shingler, R. Hawkins, A. Anthoney and R. Harrop, "Comparative Kinetics of Immune Responses and Changes in Cellular Sub-Sets Detected in Colorectal Cancer Patients Vaccinated with MVA-5T4 (TroVax) Administered Alongside Two Different Chemotherapy Regimens," Journal of Cancer Therapy, Vol. 2 No. 1, 2011, pp. 54-64. doi: 10.4236/jct.2011.21006.

References

[1] R. A. Lake and B. W. Robinson, “Immunotherapy and Chemotherapy - A Practical Partnership,” Nature Reviews Cancer, Vol. 5, No. 5, 2005, pp. 397-405.
[2] M. Rescigno, F. Avogadri and G. Curigliano, “Challenges and Prospects of Immunotherapy as Cancer Treatment,” Biochimica et Biophysica Acta, Vol. 1776, No. 1, 2007, pp. 108-123.
[3] T. Starzynska, P. J. Marsh, P. F. Schofield, S. A. Roberts, K. A. Myers and P. L. Stern, “Prognostic Significance of 5T4 Oncofetal Antigen Expression in Colorectal Carcinoma,” British Journal of Cancer, Vol. 69, No. 5, 1994, pp. 899-902.
[4] T. Starzynska, V. Rahi and P. L. Stern, “The Expression of 5T4 Antigen in Colorectal and Gastric Carcinoma,” British Journal of Cancer, Vol. 66, No. 5, 1992, pp. 867-869.
[5] E. Wrigley, A. T. McGown, J. Rennison, R. Swindell, D. Crowther, T. Starzynska and P. L. Stern, “5T4 Oncofetal Antigen Expression in Ovarian Carcinoma,” International Journal of Gynecological Cancer, Vol. 5, No. 4, 1995, pp. 269-274.
[6] J. P. Kuebler and A. de Gramont, “Recent Experience with Oxaliplatin or Irinotecan Combined with 5-Fluorouracil and Leucovorin in the Treatment of Colorectal Cancer,” Seminars in Oncology, Vol. 30, No. 4, 2003, pp. 40-46.
[7] R. Harrop, N. Drury, W. Shingler, P. Chikoti, I. Redchenko, M. W. Carroll, S. M. Kingsman, S. Naylor, A. Melcher, J. Nicholls, H. Wassan, N. Habib and A. Anthoney, “Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given alongside Chemotherapy Induces Potent Immune Responses,” Clinical Cancer Research, Vol. 13, No. 15, 2007, pp. 4487-4494.
[8] R. Harrop, N. Drury, W. Shingler, P. Chikoti, I. Redchenko, M. W. Carroll, S. M. Kingsman, S. Naylor, R. Griffiths, N. Steven and R. E. Hawkins, “Vaccination of Colorectal Cancer Patients with TroVax Given Alongside Chemotherapy (5-Fluorouracil, Leukovorin and Irinotecan) is Safe and Induces Potent Immune Responses,” Cancer Immunology, Immunotherapy, Vol. 57, No. 7, 2008, pp. 977-986.
[9] J. P. Braybrooke, A. Slade, G. Deplanque, R. Harrop, S. Madhusudan, M. D. Forster, R. Gibson, A. Makris, D. C. Talbot, J. Steiner, L. White, O. Kan, S. Naylor, M. W. Carroll, S. M. Kingsman and A. L. Harris, “Phase I Study of MetXia-P450 Gene Therapy and Oral Cyclophosphamide for Patients with Advanced Breast Cancer or Melanoma,” Clinical Cancer Research, Vol. 11, No. 4, 2005, pp. 1512-1520.
[10] R. Harrop, M. G. Ryan, H. Golding, I. Redchenko and M. W. Carroll, “Monitoring of Human Immunological Responses to Vaccinia Virus,” Methods in Molecular Biology, Vol. 269, 2004, pp. 243-466.
[11] C. Baecher-Allan, J. A. Brown, G. J. Freeman and D. A. Hafler, “CD4+CD25high Regulatory Cells in Human Peripheral Blood,” Journal of Immunology, Vol. 167, No. 3, 2001, pp. 1245-1253.
[12] A. K. Nowak, R. A. Lake and B. W. Robinson, “Combined Chemoimmunotherapy of Solid Tumours: Improving Vaccines?” Advanced Drug Delivery Reviews, Vol. 58, No. 8, 2006, pp. 975-990.
[13] E. Elkord, E. M. Alcantar-Orozco, S. J. Dovedi, D. Q. Tran, R. E. Hawkins and D. E. Gilham, “T Regulatory Cells in Cancer: Recent Advances and Therapeutic Potential,” Expert Opinion on Biology Therapy, Vol. 10, No. 11, 2010, pp. 1573-1586.
[14] S. L. Clarke, G. J. Betts, A. Plant, K. L. Wright, T. M. El-Shanawany, R. Harrop, J. Torkington, B. I. Rees, G. T. Williams, A. M. Gallimore and A. J. Godkin, “CD4 + CD25 + FOXP3 + Regulatory T Cells Suppress Anti-Tumor Immune Responses in Patients with Colorectal Cancer,” PLoS ONE, Vol. 1, No. 1, 2006, p. e129. doi:10.1371/journal.pone.0000129
[15] E. Elkord, A. Dangoor, D. J. Burt, T. D. Southgate, S. Daayana, R. Harrop, J. W. Drijfhout, D. Sherlock, R. E. Hawkins and P. L. Stern, “Immune Evasion Mechanisms in Colorectal Cancer Liver Metastasis Patients Vaccinated with TroVax (MVA-5T4),” Cancer Immunology, Immunotherapy, Vol. 58, No. 10, 2009, pp. 1657-1667.
[16] F. C. Thistlethwaite, E. Elkord, R. W. Griffiths, D. J. Burt, A. M. Shablak, J. D. Campbell, D. E. Gilham, E. B. Austin, P. L. Stern and R. E. Hawkins, “Adoptive Transfer of T(reg) Depleted Autologous T Cells in Advanced Renal Cell Carcinoma,” Cancer Immunology, Immunotherapy, Vol. 57, No. 5, 2008, pp. 623-634.
[17] M. Murai, P. Krause, H. Cheroutre and M. Kronenberg, “Regulatory T-Cell Stability and Plasticity in Mucosal and Systemic Immune Systems,” Mucosal Immunology, Vol. 3, No. 5, 2010, pp. 443-449. X. Zhou, S. L. Bailey-Bucktrout, L. T. Jeker, C. Penaranda, M. Martinez-Llordella, M. Ashby, M. Nakayama, W. Rosenthal and J. A. Bluestone, “Instability of the Transcription Factor Foxp3 Leads to the Generation of Pathogenic Memory T Cells in Vivo,” Nature Immunology, Vol. 10, No. 9, 2009, pp. 1000-1007.
[18] S. Vendetti, T. S. Davidson, F. Veglia, A. Riccomi, D. R. Negri, R. Lindstedt, P. Pasquali, E. M. Shevach and M. T. De Magistris, “Polyclonal Treg Cells Enhance the Activity of a Mucosal Adjuvant,” Immunology and Cell Biology, Vol. 88, No. 7, 2010, pp. 698-706.
[19] P. Correale, M. S. Rotundo, M. T. Del Vecchio, C. Remondo, C. Migali, C. Ginanneschi, K. Y. Tsang, A. Licchetta, S. Mannucci, L. Loiacono, P. Tassone, G. Francini and P. Tagliaferri, “Regulatory (FoxP3+) T-Cell Tumor Infiltration is a Favorable Prognostic Factor in Advanced Colon Cancer Patients Undergoing Chemo or Chemoimmunotherapy,” Journal of Immunotherapy, Vol. 33, No. 4, 2010, pp. 435-441.
[20] F. A. Sinicrope, R. L. Rego, S. M. Ansell, K. L. Knutson, N. R. Foster and D. J. Sargent, “Intraepithelial Effector (CD3+)/Regulatory (FoxP3+) T-Cell Ratio Predicts a Clinical Outcome of Human Colon Carcinoma,” Gastroenterology, Vol. 137, No. 4, 2009, pp. 1270-1279.
[21] M. E. Lutsiak, R. T. Semnani, R. De Pascalis, S. V. Kashmiri, J. Schlom and H. Sabzevari, “Inhibition of CD4(+)25+ T Regulatory Cell Function Implicated in Enhanced Immune Response by Low-dose Cyclophosphamide,” Blood, Vol. 105, No. 7, 2005, pp. 2862-2868.
[22] Y. B. Su, S. Sohn, S. E. Krown, P. O. Livingston, J. D. Wolchok, C. Quinn, L. Williams, T. Foster, K. A. Sepkowitz and P. B. Chapman, “Selective CD4+ Lymphopenia in Melanoma Patients Treated with Temozolomide: A Toxicity with Therapeutic Implications,” Journal of Clinical Oncology, Vol. 22, No. 4, 2004, pp. 610-616.
[23] P. Correale, M. G. Cusi, K. Y. Tsang, M. T. Del Vecchio, S. Marsili, M. L. Placa, C. Intrivici, A. Aquino, L. Micheli, C. Nencini, F. Ferrari, G. Giorgi, E. Bonmassar and G. Francini, “Chemo-Immunotherapy of Metastatic Colorectal Carcinoma with Gemcitabine plus FOLFOX 4 Followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Interleukin-2 Induces Strong Immunologic and Antitumor Activity in Metastatic Colon Cancer Patients,” Journal of Clinical Oncology, Vol. 23, No. 35, 2005, pp. 89
[24] P. A. Antony, C. A. Piccirillo, A. Akpinarli, S. E. Finkelstein, P. J. Speiss, D. R. Surman, D. C. Palmer, C. C. Chan, C. A. Klebanoff, W. W. Overwijk, S. A. Rosenberg and N. P. Restifo, “CD8+ T Cell Immunity against a Tumor/Self-Antigen is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells,” Journal of Immunology, Vol. 174, No. 5, 2005, pp. 2591-2601.
[25] P. A. Antony and N. P. Restifo, “Do CD4+ CD25+ Immunoregulatory T Cells Hinder Tumor Immunotherapy?” Journal of Immunology, Vol. 25, No. 3, 2002, pp. 202- 206.
[26] J. F. Curtin, M. Candolfi, T. M. Fakhouri, C. Liu, A. Alden, M. Edwards, P. R. Lowenstein and M. G. Castro, “Treg Depletion Inhibits Efficacy of Cancer Immunotherapy: Implications for Clinical Trials,” PLoS One, Vol. 3, No. 4, 2008, p. e1983.
[27] L. G. de Pillis, W. Gu and A. E. Radunskaya, “Mixed Immunotherapy and Chemotherapy of Tumors: Modeling, Applications and Biological Interpretations,” Journal of Theoretical Biology, Vol. 238, No. 4, 2006, pp. 841-862.
[28] Y. J. Ko and M. B. Atkins, “Chemotherapies and Immunotherapies for Metastatic Kidney Cancer,” Current Urology Reports, Vol. 6, No. 1, 2005, pp. 35-42.

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.